

# Causally-Interpretable Random-Effects Meta-Analysis

Justin M. Clark\*      Kollin W. Rott\*      James S. Hodges\*      Jared D. Huling\*

## Abstract

Recent work has made important contributions in the development of causally-interpretable meta-analysis. These methods transport treatment effects estimated in a collection of randomized trials to a target population of interest. Ideally, estimates targeted toward a specific population are more interpretable and relevant to policy-makers and clinicians. However, between-study heterogeneity not arising from differences in the distribution of treatment effect modifiers can raise difficulties in synthesizing estimates across trials. The existence of such heterogeneity, including variations in treatment modality, also complicates the interpretation of transported estimates as a generic effect in the target population. We propose a conceptual framework and estimation procedures that attempt to account for such heterogeneity, and develop inferential techniques that aim to capture the accompanying excess variability in causal estimates. This framework also seeks to clarify the kind of treatment effects that are amenable to the techniques of generalizability and transportability.

**Keywords:** causal inference, generalizability, transportability, meta-analysis, evidence synthesis, clinical trials

---

\*University of Minnesota School of Public Health, Division of Biostatistics

# 1 Introduction

Given data from a collection of randomized controlled trials (RCTs), an important question faced by clinicians and policy-makers alike is whether such results apply to target populations of interest. Recent work has made important advances in tackling this question by developing causal inference methods designed for meta-analysis (Dahabreh et al. 2022). These techniques are designed to account for differences between the trial and target populations, resulting in effect estimates that have a causal interpretation for the target population.

The impact of such population differences is one example of a challenge in research synthesis long recognized by practitioners of meta-analysis: between-study heterogeneity of many kinds should be taken into account when evaluating results from one trial to the next. Differences in the characteristics of populations represents just one form of between-study heterogeneity. In this paper, we develop causal quantities and estimators that build on the existing causally-interpretable meta-analysis framework to additionally take into account unexplained between-study heterogeneity beyond that induced by covariate differences between the collection of trials and the target population.

Our approach produces effect estimates that both are applicable to a target population of scientific interest and remain interpretable even when between-study heterogeneity prevents data pooling across trials. We also see our work as a conceptual bridge between the developing field of causally-interpretable meta-analysis and random-effects approaches that are well-established in evidence synthesis. This structural resemblance to traditional random-effects meta-analysis allow us to adopt some of the analytical frameworks important to that approach while retaining causal interpretability.

In principle, systematic reviews of randomized trials should have important implications for health policy and clinical practice (Berlin and Golub 2014). For example, the Strength of Recommendation Taxonomy (SORT) assigns meta-analysis to the highest level of study quality (Ebell et al. 2004). However, recent work has suggested that meta-analyses—particularly meta-analyses involving individual patient data (IPD)—have had a relatively small impact on organizations developing and publishing clinical guidelines (Vale et al. 2015), even among guidelines for which relevant IPD meta-analyses were readily available.

Analogous work published in 2021 also found limited use of systematic reviews to inform clinical guidelines: in that study, only 34% of analyzed guidelines conducted a systematic review of available evidence to inform clinical practice (Lunny et al. 2021). These authors give many possible explanations for their findings, including ignorance on the part of guideline development groups, a related over-reliance on expert opinion, and the amount of labor and time required to complete a high-quality systematic review. However, it is worth interrogating whether the low uptake of systematic reviews to inform clinical guidelines might arise

from the usefulness of the meta-analyses themselves. That is, a review of clinical evidence may be systematic, rigorous, and follow international standards while still being of limited applicability to decision-making in a particular population or setting.

Much of the relevance of a given trial to clinical practice stems from how well the patient population targeted by the practitioner aligns with trial participants. The complex, idiosyncratic process of recruitment can result in studies that, while exhibiting a high level of internal validity, are unlikely to apply to individuals distinct from trial participants, thereby reducing external validity (Degtiar and Rose 2021). Concerns over external validity are especially relevant to health system decision making, where beneficiaries may differ in key ways from participants in the RCTs that are used to justify coverage decisions. For example, a 2008 study suggested that participants in the RCTs underlying a meta-analysis informing CMS policy differed substantially from the Medicare population (Dhruva 2008). This internal-external validity gap may help to explain growing interest in the use of large electronic health records (EHR) databases to inform clinical research (Galson and Simon 2016).

Issues of relevance and external validity apply to an even greater degree when synthesizing evidence across several studies. Many of these challenges relate to possible sources of heterogeneity between the RCTs included in a given meta-analysis. Considering only one such possible difference, that of heterogeneity in the participant population underlying each RCT, it is difficult to imagine how an estimated treatment effect averaged over such populations—as is done in standard meta-analyses—would apply to a given clinician’s or health system’s population of interest. Moreover, other relevant sources of heterogeneity remain, including treatment modalities and methods of evaluating primary outcomes (Berlin and Golub 2014).

The standard approach to modeling such between-study heterogeneity is random-effects meta-analysis, in which the effects or outcomes of each study are conceived as random draws from some distribution, typically a normal distribution (Higgins, Thompson, and Spiegelhalter 2009). Heterogeneity between trials is therefore viewed as part of the total variance in trial outcomes: one component arising from sampling variation within a trial and another reflecting systematic (though still i.i.d.) variation between the trials.

However, estimates from random-effects meta-analyses still fail to explicitly account for differences between trial participants and a target population of interest to clinicians and policy makers. Recent work in causally interpretable meta-analysis has yielded methods for making population-specific inferences using data from multiple RCTs (Dahabreh et al. (2022), (2020)). Roughly, this work uses a representative sample from the target population of interest to transport treatment effects estimated in the RCT populations to the target population.

A key assumption in this approach is that two individuals from the same target population would have identical average responses to treatment regardless of which clinical trial in the meta-analysis they may have

participated in. Moreover, the treatment response observed for an individual in the target population had they participated in any one of the trials is assumed analogous to the treatment response expected in the population more generally. Systematic heterogeneity in trial conduct and the possibility of trial participation effects threaten both of these assumptions (Dahabreh, Robertson, and Hernán 2022). While some of this heterogeneity might be captured by covariate differences, other site-specific mechanisms may be unrelated to participant characteristics.

## 1.1 Examples of Between-Study Heterogeneity

Defining such heterogeneity more concretely, consider a scenario where each study in the meta-analysis applied a somewhat different version of treatment. In the context of studies designed to ameliorate lower back pain, for example, providers in one study may apply a slightly different form of spinal manipulation than providers in another study. Such differences could be pre-defined in each study’s protocol, but may also arise simply because different chiropractors implement the manipulation in slightly different ways. Moreover, differences in how a pain outcome is measured (e.g., the exact time at which the pain scale is assessed relative to treatment) could also require an expansion of potential outcome notation.

These differences in, say, treatment version, would persist even after accounting for variation in the distribution of treatment effect modifiers both between studies and between the trial and target populations. In the back pain example, if two individuals with identical covariate data enrolled in separate studies, differences in the spinal manipulation type would persist when attempting to compare and define their respective potential outcomes. This suggests indexing such heterogeneity in the potential outcomes themselves, e.g., an individual’s potential outcome had they been assigned treatment  $a$  under one provider versus another.

Broader differences in trial conduct also have the potential to induce this heterogeneity. For example, after disruptions to biomedical research caused by the COVID-19 pandemic, some clinical trials opted to deliver self-administered medications to trial participants by mail, rather than distribute them in-person (U.S. Food and Drug Administration 2021). Delivery timings under these conditions may vary significantly between different trials, e.g., trials whose participants reside in more remote, rural locations may have slower delivery times than trials in urban locations. For diseases like COVID-19, where timing of treatment affects subsequent outcomes, these differences in delivery time could induce heterogeneity in the potential outcomes from each trial.

Differences in the timing of treatments administered in-person may also have important implications for research synthesis. A recent preprint examined whether passively administered antibodies altered health outcomes associated with SARS-CoV-2 infection (Stadler et al. 2022). They found that earlier administration

of such treatments may improve their efficacy. Imagine two patients with identical baseline covariates enrolling in two studies investigating the same monoclonal antibody treatment. If the two studies differed in the timing of treatment relative to infection, this study suggests that those individuals may have distinct, study-specific expected potential outcomes.

Another example where differences in trial conduct may induce heterogeneity is when provider-assessed ratings are an outcome. For example, The Positive and Negative Syndrome Scale (PANSS) is routinely used to assess symptom severity in patients with schizophrenia (Kay, Fiszbein, and Opler 1987). For each symptom evaluated in the PANSS, raters assign a score of 1 (absent) to 7 (extreme). Differences between treatment groups might then be assessed by differences in their aggregated PANSS scores. However, individual raters may perform these qualitative evaluations in different ways. Analyses synthesizing outcomes from many sites employing different raters may need to take these differences into account.

Animated by such concerns, our work aims to lay the groundwork for a causally-interpretable meta-analysis that accounts for heterogeneity between studies beyond that induced by differences in the distribution of treatment effect modifiers. Our approach attempts to combine the techniques and intuitions of traditional random-effects meta-analysis with the causal inference-based meta-analytic framework introduced by Dahabreh et al. (2022). Concretely, this involves posing two causal questions. First, what outcomes would we observe, on average, if a member of the target population had participated in a particular study included in the collection of relevant RCTs? Moreover, what would we observe if we conducted a new RCT whose participants are drawn directly from the target population? This latter question is of primary scientific interest in this work, and follows directly from our novel framework. By answering such questions, we hope to expand the toolkit available to health policy makers and clinicians when evaluating treatment efficacy through meta-analysis.

## 2 Estimands for Capturing Between-Study Heterogeneity

Causally-interpretable meta-analysis analyzes outcomes and treatment effects observed in a collection of studies through the lens of transportability and generalizability. We assume the existence of some target population of interest and consider what this collection of studies can tell us about the effect of an intervention in that target population. Suppose we have data from a collection of clinical trials indexed by a set  $\mathcal{S} = \{1, \dots, m\}$ . One causal question of interest is: what treatment effect can we expect if a member of the target population had participated in study  $s \in \mathcal{S}$ ? As we will describe more precisely later, we can roughly describe our approach as decomposing such an average treatment effect  $\tau_s$  into the sum of an overall grand mean  $\tau$  and a

deviation  $\delta_s$  specific to study  $s$ :

$$\tau_s = \tau + \delta_s. \quad (1)$$

In such a formulation, the grand mean  $\tau$  gives the treatment effect in the target population averaged over the collection of studies while the  $\delta_s$  reflects between-study heterogeneity in the underlying treatment effect.

Our ultimate goal is to precisely characterize, estimate, and perform inference on  $\tau_0$ , which is the expected treatment effect if a new trial were conducted in the target population. Such a treatment effect comes about via a new draw  $\delta_0$ , a new shift about  $\tau$ .

The decomposition in (1) is structurally similar to parameters studied in random-effects meta-analysis, wherein study-specific treatment effects are assumed to be i.i.d. draws from a distribution, typically normal. In this work, we define and estimate parameters that maintain the familiar form of (1) while admitting a precise causal interpretation. This is accomplished by incorporating the study-specific heterogeneity reflected in  $\delta_s$  within the potential outcomes framework. Specifically, we incorporate the variation represented by  $\delta_s$  as an additional argument to the standard potential outcomes notation.

## 2.1 The Data

Adding notation to the example outlined above, suppose we have IPD from a collection of  $m$  trials, all of which examined the same set of treatments. Again, we index these trials with the set  $\mathcal{S} = \{1, \dots, m\}$  and treatments with the set  $\mathcal{A}$ . For each participant  $i$  in a given trial  $s \in \mathcal{S}$  with  $n_s$  participants total, we have outcome data  $Y_i$ , baseline covariate information  $X_i$  and treatment assignment  $A_i$ , where  $A_i \in \mathcal{A}$ . We also assume to have baseline covariate information from a random sample of individuals in a target population of interest; we do not require treatment or outcome information in this sample. As in Dahabreh et al. (2022), we let  $S = 0$  for individuals in the target population and introduce another variable  $R$  which takes value 1 for participants in the collection of trials and 0 for members of the target population. Thus, the observed data for each individual in the full dataset—that is, combined data from both the collection of trials and the target population—is of the form

$$(R_i Y_i, R_i A_i, X_i, S_i).$$

$R_i Y_i$  and  $R_i A_i$  evaluate to zero for those in the target population, indicating that such data are unavailable. The total sample size including both the sample from the target population and the collection of trials is  $n = n_0 + n_1 + \dots + n_m$ .

## 2.2 Rationale for New Causal Quantities

In introducing causally-interpretable meta-analysis, Dahabreh et al. (2022) define potential outcomes  $Y(a)$  that depend on the assigned treatment  $a \in \mathcal{A}$ . Different causal estimands describe the distribution of these potential outcomes within various populations of interest. For instance,  $E[Y(a)|R = 0]$  gives the expected potential outcome under treatment  $a$  in the target population. To identify quantities like  $E[Y(a)|R = 0]$ , Dahabreh et al. assume exchangeability in potential outcomes across values of  $S$ , conditional on baseline covariates. They also show that  $E[Y(a)|R = 0]$  is identifiable under the weaker assumption of mean exchangeability, roughly defined as the assumption that:

$$E[Y(a)|X = x, S = 0] = E[Y(a)|X = x, S = s] \quad (2)$$

for  $s = 1, \dots, m$ , along with additional conditions ensuring that the assumption is only made across values of  $S$  where the covariate pattern  $X = x$  has positive probability of occurring.

Intuitively, the primary risk in assuming (2) when it does not, in fact, hold is that the particular idiosyncrasies of each trial have the potential to muddle a transported treatment effect estimated from pooled data. This is especially problematic if the trials in the meta-analytic collection differ a great deal in sample size. In that setting, violations of (2) may result in causal estimates that are heavily weighted to the particular conditions of the largest trial. Such a weighting scheme has no clinical meaning and is merely an artifact of the mean exchangeability assumption.

The motivation for referencing such between-study heterogeneity stems directly from the logic underlying standard random-effects meta-analysis (Higgins, Thompson, and Spiegelhalter 2009). In that paradigm, a meta-analysis of a collection of trials proceeds under the assumption that the underlying parameter of interest—typically an average treatment effect—differs between trials. More precisely, in the traditional random-effects model, each study’s latent true treatment effect is assumed to be randomly sampled from a distribution of effects. The variance of this underlying distribution is often of interest, and serves to quantify the degree of between-study heterogeneity.

Our proposed method models the average effects arising from studies  $s \in \mathcal{S}$  transported to the target population as varying about a grand mean according to draws of a latent random variable. Draws of this latent random variable fix these underlying average effects at different values, where differences between these values reflect between-study heterogeneity beyond that induced by covariate differences. The key distinction between these methods and traditional random-effects models is that heterogeneity in underlying parameter values (e.g., heterogeneity between studies in treatment effects) stems from variation in the potential outcomes of study participants, thereby retaining causal interpretations absent from standard meta-analysis.

Recall that a key causal question motivating this study is: what outcome would we expect if an individual were assigned treatment  $a \in \mathcal{A}$  in study  $s \in \mathcal{S}$ ? This question suggests a need to distinguish potential outcomes arising from one trial setting versus another. Using the notation of VanderWeele and Hernán (2013), we write the potential outcome of a subject receiving treatment  $a \in \mathcal{A}$  under the conditions present in study  $s \in \mathcal{S}$  as having two arguments: one specifying the treatment assignment and another fixing the conditions present in a given setting, e.g., treatment group  $a$  in study  $s$ :

$$Y(a, k_s^a).$$

Here,  $k_s^a$  constitutes a realization of a random variable  $K_s^a(a)$ . Because we conceptualize values for  $K_s^a(a)$  even for individuals who did not receive treatment  $a$  in study  $s$ , its notation mimics that of a standard potential outcome, as one's experience in a particular study could be a function of the treatment received. We suppose that each combination of a study and treatment arm is associated with one such random variable, the collection of which, across studies for a given treatment  $a$ , is an i.i.d. sample from some common distribution:

$$K_1^a(a), \dots, K_m^a(a) \stackrel{i.i.d.}{\sim} F_{K^a(a)}.$$

We do not impose a particular interpretation on  $K_s^a(a)$  except that it reflects the conditions an individual would have experienced had they been in treatment group  $a$  of study  $s$ . That is, two individuals with common values of this random variable can be understood to have been assigned treatment  $a$  under equivalent conditions. Again, we treat  $K_s^a(a)$  as a potentially counterfactual variable which fixes the heterogeneity in setting/treatment group combinations even for individuals who were not assigned treatment  $a$  or did not participate in study  $s$ .

We suppose these random variables are an i.i.d. sample from some common distribution not because we think this gives the most accurate approximation to the data generating process that induces between-study heterogeneity. Rather, such an assumption constitutes our best guess as to the nature of this heterogeneity in the absence of additional information. Equipped with only outcome, baseline covariate, and treatment arm information, residual between-study heterogeneity is as good as i.i.d. noise from the perspective of the (meta) analyst, playing a role similar to residual errors in a simple linear regression model. If more information were available about the nature of between-trial heterogeneity, this assumption could be relaxed or refined.

The impact of this heterogeneity is related to but distinct from the effects of trial participation per se, as studied in Dahabreh et al. (2019). Here, we develop a conceptual framework for understanding the effects of participating in one trial versus another rather than participation in and of itself. In part, this effort can be



interpreted as clarifying the interpretation of causal estimands defined in earlier work on causally-interpretable meta-analysis. Recognizing the impact of between-trial heterogeneity, we study the effects of participation in one of the trials under study, or trials similar to those under study, rather than a more generic effect of treatment assignment in the target population.

### 2.3 Defining Causal Estimands

As in Dahabreh et al. (2022), our interest is in transporting inferences from the collection of trials to a target population. Since the realized draw of  $K_s^a(a) = k_s^a$  indexes the heterogeneity in potential outcomes arising from trial  $s$ , a causal quantity relevant to evaluating the kind of outcomes we would observe had members of the target population participated in trial  $s$  is

$$\mu_{a,0}(k_s^a) = E[Y(a, k_s^a) | R = 0]. \quad (3)$$

This is a fixed quantity which can be interpreted as the average potential outcome in the target population where the heterogeneity in application of treatment  $a$  is fixed at the value associated with trial  $s$ .

We recognize that policy makers and clinicians are often most interested in treatment *effects* within their target population, rather than mean potential outcomes alone. In this paper, we focus our attention on mean potential outcomes for simplicity of presentation. However, contrasts of causal quantities like (3), e.g.

$$\tau_{a,a'}^s = \mu_{a,0}(k_s^a) - \mu_{a',0}(k_s^{a'}) = E[Y(a, k_s^a) | R = 0] - E[Y(a', k_s^{a'}) | R = 0]$$

can be defined corresponding to average treatment effects in the target population under the conditions of trial  $s$ . Focus on such effects also allows relaxation of mean exchangeability assumptions on mean potential outcomes to be replaced by mean effect exchangeability.

Returning our focus to (3), note that the random variables whose  $m$  realized values give these transported potential outcomes for each study are a function of the latent random sample  $K_1^a(a), \dots, K_m^a(a)$ :

$$\mu_{a,0}(a, K_1^a(a)), \dots, \mu_{a,0}(a, K_m^a(a)) \quad (4)$$

As such, they also constitute a simple random sample from some distribution.

We assume this random sample  $\mu_{a,0}(K_1^a(a)), \dots, \mu_{a,0}(K_m^a(a))$  arises from a distribution with mean  $\mu_{a,0}$  and finite variance. Without any further modeling assumptions, we can decompose each such random variable

in the sample as:

$$\mu_{a,0}(K_s^a(a)) = \mu_{a,0} + \Delta_{0,s}^a, \quad (5)$$

where  $\Delta_{0,s}^a$  is a random variable with mean zero and finite variance. Note that (5) does not impose any particular modeling assumption on  $\mu_{a,0}(K_s^a(a))$ ; it simply labels random variation about its expectation over  $K_s^a(a)$  as  $\Delta_{0,s}^a$ . Rearranging (5), we have

$$\begin{aligned} \Delta_{0,s}^a &= \mu_{a,0}(K_s^a(a)) - \mu_{a,0} \\ &= \mu_{a,0}(K_s^a(a)) - E_{K^a(a)}[\mu_{a,0}(K_s^a(a))]. \end{aligned}$$

The decomposition in (5) allows us to better understand the role that the latent random variables  $K_s^a(a)$  play in driving systematic differences between studies in causal quantities. Namely, a draw of  $K_s^a(a) = k_s^a$  corresponds to a realization of  $\Delta_{0,s}^a = \delta_{0,s}^a$  which in turn shifts the average potential outcome under  $a$  transported from study  $s$  to the target population.

Recalling the stylized version of our approach in Equation (1), our model for the treatment effect we would observe if a member of the target population had been assigned to treatment  $a$  vs.  $a'$  in study  $s$  is therefore

$$\begin{aligned} \mu_{a,0}(k_s^a) - \mu_{a',0}(k_s^{a'}) &= \mu_{a,0} + \delta_{0,s}^a - (\mu_{a',0} - \delta_{0,s}^{a'}) \\ &= (\mu_{a,0} - \mu_{a',0}) + (\delta_{0,s}^a - \delta_{0,s}^{a'}). \end{aligned} \quad (6)$$

We can conceptualize  $\tau_{a,a',0} = \mu_{a,0} - \mu_{a',0}$  as the “grand mean effect” of treatment  $a$  vs.  $a'$  in the target population and  $\delta_{0,s}^a - \delta_{0,s}^{a'}$  as the heterogeneity of that overall effect when transporting from the setting of study  $s$ . These two quantities stand in for  $\tau$  and  $\delta_s$ , respectively in Equation (1).

Besides considering the expected potential outcome if an individual from the target population participated in one of the trials in our collection, we might also ask: what potential outcomes would we expect if a new trial were conducted that recruited a simple random sample from the target population? We make an important assumption here that the same random process which induces heterogeneity in expected potential outcomes within the collection of trials would apply to a new trial of the same collection of treatments.

We can represent this assumption by adding  $K_0^a(a)$  to our original random sample:

$$K_1^a(a), \dots, K_m^a(a), K_0^a(a) \stackrel{i.i.d.}{\sim} F_{K^a(a)}$$

and defining  $\mu_{a,0}(k_0^a)$  and  $\mu_{a,0}(K_0^a(a))$  as previously.

This framing is analogous to the idea in random-effects meta-analysis that we can make inferences for the treatment effects of studies that are not included in the meta-analysis (Higgins, Thompson, and Spiegelhalter 2009). Again, our i.i.d. assumption regarding  $K_0^a(a)$  reflects our best guess as to the random process governing between-study heterogeneity. In the absence of additional information, we posit both that the same sources of heterogeneity that induce systematic differences between RCTs in the trial sample would apply to a hypothetical RCT in the target population and that this additional variation stems from i.i.d. draws from a common distribution. As explained below, we use this assumption when producing prediction intervals that contain  $\mu_{a,0}(k_0^a)$  with some specified probability.

There are several possible motivations for estimating the outcomes in an unobserved trial. One is as an input to planning and preparation for new clinical studies. Clinicians may desire to estimate treatment effects they might expect in a planned study with participants similar to members of the target population. Alternatively, transported estimates from a clinical trial might serve as a kind of bound for effects we are likely to observe in practice. Estimating outcomes in an unobserved trial also produces such a bound, albeit one not overly influenced by the idiosyncrasies present in any particular study in the collection of trials.

### 3 Identification and Estimation of Causal Quantities

#### 3.1 Identification

We first consider identification of  $\mu_{a,0}(k_s^a)$ , which gives the expected outcome that would have been observed if a member of the target population had been assigned treatment  $a$  in study  $s$ . To express this as a functional of the observed data, we make the following identifying assumptions, many of which are similar to those in Dahabreh et al. (2022) and VanderWeele and Hernán (2013):

**1. Exchangeability in mean between trials:**

$$E[Y(a, k_s^a)|X = x, S = s_1] = E[Y(a, k_s^a)|X = x, S = s_2]$$

for all  $s_1, s_2 \in \{0, 1, \dots, m\}$  and  $x \in \mathcal{X}$  such that  $f(x, S = s_1) \neq 0$  and  $f(x, S = s_2) \neq 0$ . Note here that the heterogeneity in trial  $s_1$  and  $s_2$  is fixed at  $k_s^a$  in both settings.

**2. Exchangeability over treatment groups within a trial:**

$$Y(a, k_s^a) \perp\!\!\!\perp A|(X, S = s)$$

for all  $a \in \mathcal{A}$ ,  $k_s^a \in \mathcal{K}^a$ , and  $s \in \mathcal{S}$ .

3. **Consistency:** If  $A_i = a$  and  $K_i^a(a) = k^a$  for individual  $i$ , then  $Y_i(a, k^a) = Y_i$ .
4. **Positivity:** For all  $s \in \mathcal{S}$ , if  $f(x, R = 0) \neq 0$ , then  $P(S = s | X = x) > 0$ .
5. **Distribution of  $K^a(a)$ :** For  $s = 1, \dots, m$  and  $a \in \mathcal{A}$  each random variable  $K_s^a(a)$  constitutes an i.i.d. draw from a distribution  $F_{K^a(a)}$ .
6. **Constancy of  $K^a(a)$  by treatment group/study:** Within each treatment group  $a$  and study  $s$ , the value of  $K^a(a)$  for each participant is fixed at the realized value of  $K_s^a(a) = k_s^a$ . That is, if  $A = a$  and  $S = s$ , then

$$K_i^a(a) = K_s^a(a) = k_s^a$$

for  $i \in 1, \dots, n_s$ .

Assumptions 3 and 5 involve a slight abuse of notation, wherein we define a random variable  $K_i^a(a)$  giving the version of treatment for individual  $i$ . The key point here is that such a random variable takes on the same realized value of  $K_s^a(a)$  for all participants in trial  $s$ . Alternatively, one might assume a hierarchical model where each individual in treatment arm  $a$  and study  $s$  has an associated random variable  $(K_s^a(a))_i$ ,  $i = 1, \dots, n_s$ , centered at a the realized value of  $K_s^a(a) = k_s^a$ . In this paper, we focus on trial/treatment group-wide heterogeneity to greatly simplify the mathematical presentation. However, a hierarchical model of the kind proposed above can—under certain assumptions—lead to the same identification results presented here.

Under these assumptions, we identify  $\mu_{a,0}(k_s^a)$  as

$$\psi_{s,0}(a) = E[E[Y|X, S = s, A = a] | R = 0]. \quad (7)$$

That is, we average a regression function relating outcomes under treatment  $a$  in study  $s$  to covariates  $X$  over the distribution of such covariates in the observed target population. (A full proof of this result is given in the Appendix.) This observed data functional is analogous to that identified in Equation (6) of Theorem 1 in Dahabreh et al. (2022), with  $R = 1$  in their case replaced by  $S = s$  in ours.

### 3.2 Estimation

Letting  $g_a^s(X) = E[Y|X, S = s, A = a]$ , we could apply an outcome model/standardization approach that averages an estimate  $\hat{g}_a^s(X)$  of  $E[Y|X, S = s, A = a]$  over the distribution of covariates in the target

population:

$$\hat{\psi}_{s,0}(a) = \left\{ \sum_{i=1}^n I(S_i = 0) \right\}^{-1} \sum_{i=1}^n I(S_i = 0) \{ \hat{g}_a^s(X_i) \}$$

Another option involves inverse probability weighting, in which the outcomes observed among participants in study  $s$  are weighted by the similarity of each participant to members of the target population. The estimator applying this approach is given by

$$\hat{\psi}_{s,0}^{ipw}(a) = \left\{ \sum_{i=1}^n I(S_i = 0) \right\}^{-1} \sum_{i=1}^n \left( \frac{I(A_i = a)}{\hat{e}_a^s(X_i)} \right) I(S_i = s) \frac{\hat{p}_0(X_i)}{\hat{p}_s(X_i)} Y_i$$

where  $\hat{p}_0(X_i)$  estimates  $P(R = 0|X_i)$ ,  $\hat{e}_a(X_i)$  estimates  $P(A_i = a|S = s, X_i)$ , and  $\hat{p}_s(X_i)$  estimates  $P(S = s|X_i)$ . Identification of this result, proceeding from (7) is given in the appendix.

A final option is the so-called augmented inverse probability weighting (AIPW) estimator, which combines the two approaches introduced above:

$$\hat{\psi}_{s,0}^{aipw}(a) = \left\{ \sum_{i=1}^n I(S_i = 0) \right\}^{-1} \sum_{i=1}^n \left[ I(S_i = 0) \{ \hat{g}_a^s(X_i) \} + \left( \frac{I(A_i = a)}{\hat{e}_a^s(X_i)} \right) I(S_i = s) \frac{\hat{p}(X_i)}{1 - \hat{p}(X_i)} (\hat{g}_a^s(X_i) - Y_i) \right]$$

This approach adds a correction to the outcome model approach via inverse probability weighting over the residuals of the outcome model for arm  $a$  of study  $s$ .

Our second causal quantity of interest is  $E[Y(a, k_0^a)|R = 0]$ , where  $k_0^a$  is the realized value of the random variable  $K_0^a(a)$  described in the previous section. In the absence of additional information concerning the distribution  $F_{K^a(a)}$ , our estimation strategy for  $E[Y(a, k_0^a)|R = 0]$  relies on the following approximation, the full details of which are included in the Appendix:

$$\begin{aligned} E[Y(a, K_0^a(a))|R = 0] &= \sum_{k^a \in \mathcal{K}^a} E \{ E[Y(a, K_0^a(a))|R = 0, K_0^a(a) = k^a]|R = 0 \} P(K_0^a(a) = k^a) \\ &\approx \sum_{k^a \in \mathcal{K}^a} E \{ E[Y(a, K_0^a(a))|R = 0, K_0^a(a) = k^a]|R = 0 \} \left\{ \frac{1}{m} \sum_{s=1}^m \mathbb{1}(k^a = k_s^a) \right\} \\ &= \frac{1}{m} \sum_{s=1}^m E[Y(a, k_s^a)|R = 0] \\ &= \frac{1}{m} \sum_{s=1}^m E[E[Y|X, S = s, A = a]|R = 0] && \text{by (7)} \\ &= \frac{1}{m} \sum_{s=1}^m \psi_{s,0}(a). \end{aligned}$$

Again, taking contrasts of the above quantity applied to different treatments implies identification

of treatment effects of interest, e.g., causal quantities of the form given in (6). We can then estimate  $\frac{1}{m} \sum_{s=1}^m \psi_{s,0}(a)$  using any of the methods discussed above for estimating each  $\psi_{s,0}(a)$  individually. For instance, we might estimate this quantity using

$$\frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a) = \frac{1}{m} \sum_{s=1}^m \left( \left\{ \sum_{i=1}^n I(S_i = 0) \right\}^{-1} \sum_{i=1}^n \{\hat{g}_a^s(X_i)\} \right).$$

### 3.3 Estimation of Between-Study Variability

A central parameter of interest in traditional random-effects meta-analysis is the between-study variance, which describes the variability of the effects underlying each study. Recalling the decomposition given in (5), the analogous parameter in our work is the variance of  $\Delta_{0,s}^a$ , which specifies the variability between studies in the transported mean potential outcomes. We propose an estimate of this variance inspired by the method of moments approach derived by Rao et al. (1981) and subsequently applied by DerSimonian and Laird (1986) in their seminal work on random-effects meta-analysis. The key distinction between our estimate and the traditional random-effects estimate is that, in practice, the estimates for  $\mu_{a,0}(k_1^a), \dots, \mu_{a,0}(k_m^a)$  are correlated due to their dependence on the same sample from the target population. This correlation complicates the derivation and form of the resulting estimator.

In the derivation below, we consider estimating between-study variability in a highly general setting; the only relationship to our causal framework is that of correlation between study-specific estimates. Operating in a simplified setting, suppose we have  $m$  study-specific means  $\mu_1, \dots, \mu_m$  drawn from a distribution  $F_\mu$  with mean  $\mu$  and variance  $\gamma^2$ . The analogy to our setting is obtained by letting  $\mu_s = \mu_{a,0}(k_s^a)$ . We estimate these means with  $\hat{\mu}_1, \dots, \hat{\mu}_m$  each of which is individually unbiased for its respective study-specific mean. The analogous quantities for us are  $\hat{\mu}_s = \hat{\psi}_{s,0}(a)$ . We estimate the grand mean  $\mu$  using a weighted sum of the study-specific estimates  $\hat{\mu} = \sum_{s=1}^m w_s \hat{\mu}_s$ , where  $\sum_{s=1}^m w_s = 1$ . (For instance, we might have  $w_s = \frac{1}{m}$  when taking a simple average.) Also, let  $\text{Var}(\hat{\mu}_s | S = s) = \sigma_s^2$  denote the sampling variance of each study-specific estimator and  $\text{Var}(\hat{\mu}_s) = \sigma_s^2 + \gamma^2$ , which reflects both within- and between-study variance. Letting  $Q = \sum_{s=1}^m (\hat{\mu}_s - \hat{\mu})^2$  and  $C_s = -2 \sum_{i \neq s} w_i (1 - w_s) \sigma_{is} + \sum_{i \neq s} \left[ \sum_{j \neq i, j \neq s} w_i w_j \sigma_{ij} \right]$  we can show that

$$E[Q] = m \sum_{s=1}^m w_s^2 (\sigma_s^2 + \gamma^2) + \sum_{s=1}^m [(1 - 2w_s)(\sigma_s^2 + \gamma^2) + C_s].$$

A moment-based estimator for  $\gamma^2$  is then given by the value  $\tilde{\gamma}^2$  that satisfies

$$\sum_{s=1}^m (\hat{\mu}_s - \hat{\mu})^2 = m \sum_{s=1}^m w_s^2 (\sigma_s^2 + \tilde{\gamma}^2) + \sum_{s=1}^m [(1 - 2w_s)(\sigma_s^2 + \tilde{\gamma}^2) + C_s].$$

Solving for such a  $\tilde{\gamma}^2$ , we obtain

$$\tilde{\gamma}^2 = \frac{\sum_{s=1}^m (\hat{\mu}_s - \hat{\mu})^2 - \sum_{s=1}^m \sigma_s^2 \{mw_s^2 + (1 - 2w_s)\} - \sum_{s=1}^m C_s}{\sum_{s=1}^m \{mw_s^2 + (1 - 2w_s)\}}.$$

Our final estimate for the between-study heterogeneity would then be

$$\hat{\gamma}^2 = \max(0, \tilde{\gamma}^2). \quad (8)$$

A full derivation of the above estimator is given in the Appendix. The key distinction between our estimator and the traditional random-effects estimator introduced by Rao et al. (1981) is the inclusion of  $-\sum_{s=1}^m C_s$  in the numerator of  $\hat{\gamma}^2$ . This has the effect of “correcting” the traditional estimator to account for the nonzero correlation between study-specific estimates. Beyond our setting, the estimator can be generally applied to any analysis which takes a weighted average of correlated quantities to estimate some underlying grand mean; note, though, that it is subject to bias when individual estimates are themselves biased.

### 3.4 Inference for Outcomes in a New Trial

Inference for the outcomes we would expect if members of the trial population participated in an *observed* trial, e.g.,  $\mu_{a,0}(k_s^a)$ ,  $s \in \mathcal{S}$  can proceed in a variety of ways, including simple bootstrap resampling on data from the target population and study  $s$  or via asymptotic approximations to the sampling distribution of  $\hat{\psi}_{s,0}(a)$ . Here, we focus on inference for  $\mu_{a,0}(K_0^a(a))$ . We keep  $K_0^a(a)$  as a random variable in this estimand since it refers to outcomes in a trial we have yet to observe. As such, a simple bootstrap applied to all observed trials and the target population would fail to capture the excess variability induced by conducting a new trial. That is, our prediction intervals aim to capture both the sampling variability of our estimator  $\frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a)$  as reflected in the observed data and additional uncertainty about the unobserved trial. We can make progress under the assumption that the unobserved trial is subject to similar heterogeneity as that between the observed trials. Here, we propose three methods for constructing these prediction intervals, and later evaluate them in a simulation experiment.

#### 3.4.1 Inference Based on $\hat{\gamma}^2$

Above, we derived an estimator  $\hat{\gamma}^2$ , which we generically interpret as an estimate of between-study heterogeneity beyond that induced by measured covariates. When we replace  $\hat{\mu}_s$  with  $\hat{\psi}_{s,0}(a)$  and  $\hat{\mu}$  with  $\frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a)$ ,  $\hat{\gamma}^2$  then estimates  $\text{Var}(\mu_{a,0}(K_s^a(a)))$ . That is, within our framework,  $\hat{\gamma}^2$  quantifies the variability in expected transported potential outcomes from one trial to another, where the variability is driven by setting-specific

heterogeneity. To construct a prediction interval centered at  $\frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a)$ , we employ the same form of the interval considered in Higgins et al. (2009) for inference on “the effect in an unspecified study”:

$$\frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a) \pm t_{m-2}^\alpha \sqrt{\hat{\gamma}^2 + \widehat{\text{Var}} \left( \frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a) \right)}, \quad (9)$$

where  $\widehat{\text{Var}} \left( \frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a) \right)$  is obtained using a simple bootstrap on all of the observed studies and the target population, and  $t_{m-2}^\alpha$  is the  $(1 - \alpha)$ th quantile of the  $t$  distribution with  $m - 2$  degrees of freedom.

### 3.4.2 Inference Based on the Bootstrap

One way to approximate the difference between our observed estimates and that of an unobserved trial is to compute  $\frac{1}{m-1} \sum_{s=1}^{m-1} \hat{\psi}_{s,0}(a)$  using data from a subset of  $m - 1$  trials and compare this result with that of the transported potential outcome from the  $m$ th, left-out trial (as repeated for all trials). This procedure aims to capture variability related to between-trial heterogeneity. To additionally capture sampling variability in the observed data, we couple the leave-one-out approach with application of the simple or wild bootstrap. Both such bootstraps are described below. The result of both procedures is to construct an estimate for the distribution of  $\mu_{a,0}(K_s^a(a))$ . For ease of notation in the following, we let  $\hat{\mu}_0 = \frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a)$  and  $\hat{\mu}_s = \hat{\psi}_{s,0}(a)$ .

Let  $D_s$  denote all of the data available in our original sample from trial  $s = 1, \dots, m$ . Let  $X$  denote the covariate data available from the target population. For  $b = 1, \dots, B$ ,

1. Randomly choose one of  $m$  studies to treat as the “unobserved” trial on which we’re trying to make a prediction. Denote this choice  $s_b \in \{1, \dots, m\}$ .
2. Draw a simple bootstrap sample  $D_{s_b}^*$  from  $D_{s_b}$  and  $X_1^*$  from  $X$  and estimate  $\hat{\mu}_{s_b}^*$  using these two datasets.
3. Draw simple bootstrap samples  $\{D_s^* : s \neq s_b\}$  from the other trial data. Draw another bootstrap sample  $X_2^*$  from  $X$ . With these samples, compute  $\mu^* = \frac{1}{m-1} \sum_{s \neq s_b} \hat{\mu}_s^*$ .
4. Compute an estimated residual  $\hat{\delta}_b^* = \mu^* - \hat{\mu}_{s_b}^*$  that quantifies our prediction error
5. Finally, construct another estimate  $\hat{\mu}^*$  using a new set of bootstrap samples for all of the original data, including the trial that we left out when computing the prediction error. Let  $\hat{\mu}_b^{\text{pred}} = \hat{\mu}^* - \hat{\delta}_b^*$ .

We also consider constructing prediction intervals using the wild bootstrap based on the influence function of the estimator  $\hat{\mu}_s$ . This procedure follows an outline similar to the simple bootstrap above, except that the approach of Matsouaka et al. (2022) replaces sampling the data with replacement. Note that the exact form



of the influence function depends on the estimator. Because we use the outcome model in the simulation study described below, we use its influence function in implementing the wild bootstrap. See, e.g., Tsiatis (2006) for additional detail regarding the definition and derivation of influence functions.

## 4 Simulation Study

To evaluate the performance of the three approaches outlined above, we conduct a simulation study as follows.

### 4.1 Data Generating Procedure

*Covariates:* We assume we have three covariates  $X_1, X_2, X_3$  for each of the  $m$  trials and the sample from the target population. Each trial has 100 participants total, split into two treatment groups, and the target population sample is of size 1000. The covariates in each setting  $s = 0, 1, \dots, m$  are generated as follows:

1. Determine the mean covariate vector  $\boldsymbol{\mu}_s \in \mathbb{R}^3$  in study  $s$  by generating  $m$  equally spaced values in the interval  $[0, 1.5]$  and setting  $\boldsymbol{\mu}_s$  equal to the  $s$ th such value (repeating the value three times for each entry in  $\boldsymbol{\mu}_s$ ). Thus, if  $m = 3$ , then  $\boldsymbol{\mu}_1 = (0, 0, 0)^T$ ,  $\boldsymbol{\mu}_2 = (0.75, 0.75, 0.75)^T$ , and  $\boldsymbol{\mu}_3 = (1.5, 1.5, 1.5)^T$ . In every scenario, the mean covariate vector in the target population is  $\boldsymbol{\mu}_0 = (1, 1, 1)^T$ .
2. For each of  $n_s$  participants in study  $s$ , draw a vector  $(\mathbf{X}_s)_i \sim \mathcal{N}(\boldsymbol{\mu}_s, \Sigma)$ , where

$$\Sigma = \begin{pmatrix} 1 & 0.5 & 0.5 \\ 0.5 & 1 & 0.5 \\ 0.5 & 0.5 & 1 \end{pmatrix}.$$

Note that this matrix is identical across studies and the target population.

*Potential Outcomes:* Equipped with these covariate values, we generate each participant's potential outcome under treatment  $a$  in study  $s$  as a linear combination of  $(X_{s,1}, X_{s,2}, X_{s,3})_i^T$ . That is,

$$(Y(a, k_s^a) | S = s, \mathbf{X} = \mathbf{x})_i = \beta_0 + \beta_1 x_{s,1} + \beta_2 x_{s,2} + \beta_3 x_{s,3} + \delta_s^a + \epsilon, \quad (10)$$

where  $\beta_0 = \beta_1 = \beta_2 = \beta_3 = 0.5$  and  $\epsilon \sim N(0, 1)$ . The value  $\delta_s^a$  is the realized value of random variation in potential outcomes that results from applying treatment  $a$  in study  $s$ ; it is fixed across all participants in study  $s$ . The distribution of this variation is distinct in different simulation scenarios, as detailed below.

Under the specification in (10), the true value for the estimand of interest is

$$\begin{aligned}
E[Y(a, k_0^a)|R = 0] &= E[E[Y(a, k_0^a)|S = 0, \mathbf{X}]] = 0.5 + 0.5E[X_{0,1}] + 0.5E[X_{0,2}] + 0.5E[X_{0,3}] + \delta_0^a + E[\epsilon] \\
&= 0.5 + 0.5(1) + 0.5(1) + 0.5(1) + \delta_0^a + 0 \\
&= 2 + \delta_0^a.
\end{aligned} \tag{11}$$

This is the true expected value under treatment  $a$  if members of the target population participated in an “unobserved” trial. Treatment assignment in each observed trial to  $a$  or placebo proceeds under 1:1 randomization.

*Estimation:* Using notation defined earlier, we estimate the average observed outcome under treatment  $a$  in study  $s$  (denoted  $g_a^s(x) = E[Y|X = x, S = s, A = a]$ ) using a correctly specified outcome model

$$\hat{g}_a^s(x) = \mathbf{x}^T \hat{\boldsymbol{\beta}}_s,$$

where  $\mathbf{x}^T = (1, x_1, x_2, x_3)^T$  and  $\boldsymbol{\beta}_s = (\beta_{s,0}, \beta_{s,1}, \beta_{s,2}, \beta_{s,3})^T$ . The expected value of this outcome averaged over the distribution of covariates in the target population (denoted  $\psi_{s,0}(a) = E[E[Y|X, S = s, A = a]|R = 0]$ ) is estimated as

$$\hat{\psi}_{s,0}(a) = \frac{1}{n_0} \sum_{i:S_i=0} \hat{g}_a^s(X_i).$$

As described above, the average of the  $\psi_{s,0}(a)$ ’s over the  $m$  studies is our best guess of the target estimand  $\mu_{a,0}(k_0^a)$ :

$$\hat{\mu}_{a,0}(k_0^a) = \frac{1}{m} \sum_{s=1}^m \hat{\psi}_{s,0}(a).$$

We then construct a prediction interval centered at  $\hat{\mu}_{a,0}$  which aims to contain  $E[Y(a, k_0^a)|R = 0] = 2 + \delta_0^a$  with some pre-specified probability, using the three methods described above.

## 4.2 Simulation Scenarios

The above data generating process is highly simplified. It assumes the true outcome model is identical across scenarios and that we specify this model correctly. Future work will complicate this setup to investigate other issues, e.g, model misspecification. For now, this simple scenario focuses our attention on two main parameters, which we vary across simulations:

1. *The number of trials in the meta-analysis study dataset.* This takes values across  $m = 5, 10, 15, 30$ , and 50 studies. While we rarely expect to have 50 studies in a meta-analysis, the goal of that scenario is to

investigate whether a given method over/under covers as we collect data from more and more studies.

2. *The distribution of the setting-specific variation.* Settings include:  $\text{Unif}[-2, 2]$ ,  $N(0, 1)$ ,  $\text{Exponential}(1) - 1$ , and  $\text{Pareto}(1, 3)$ .

The settings above define  $5 \times 4 = 20$  distinct simulation scenarios. We evaluate each scenario with 1000 artificial datasets simulated from the data generating process described above. Where applicable, any application of the bootstrap in our estimation procedure includes 1000 replications. For a given method of constructing the prediction interval of interest, we estimate the coverage probability as the proportion of prediction intervals across those 1000 iterations that contain the true parameter value.

### 4.3 Results

Figure 1 displays estimates of coverage for prediction intervals constructed according to the quantiles of the bootstrap estimates. The second set of plots does so using using an approximation to the normal distribution, i.e., the mean of the bootstrapped estimates  $\pm 1.96$  times the standard deviation of the bootstrapped estimates. In the figure, Method of Moments refers to intervals constructed using our estimate of  $\hat{\gamma}^2$ , as in (9). (Note that the Method of Moments results are the same in both figures because they do not depend on such choices.)

In general, the method of moments intervals based on the corrected estimator of between-study variance perform better than bootstrap-based alternatives across different distributions of residual heterogeneity. The normal-based approximations for the bootstrap approaches also outperform prediction intervals based on empirical quantiles, though the normal-based approximations are still outperformed by the method of moments estimator. Although simulations assuming a very large number of MA studies are helpful for understanding aspects of our approaches' asymptotic behavior, we recognize that 15 or more studies is larger than the vast majority of meta-analysis datasets, especially given the need for IPD. Thus, these simulation results suggest applying the method of moments intervals based on the corrected estimator of between-study variance in most circumstances when researchers are interested in estimating effects measured in a new, unobserved trial recruited from the target population.

Although the performance of the two bootstrap alternatives is similar, we note that the wild bootstrap has non-negligible computational advantages. On a standard Windows machine with an Intel Core i7-9700 Processor, the wild bootstrap approach generated prediction intervals more than twice as fast as the simple bootstrap in a scenario with 5 studies and the sample sizes given above. The absolute times in such cases were negligible (16 seconds vs. 6 seconds); however, with more studies and a much larger target population sample, the wild bootstrap becomes far more computationally attractive.




Figure 1: Coverage for prediction intervals constructed according to the quantiles of the bootstrap estimates. Each plot corresponds to a separate distribution for setting-specific variation.




Figure 2: Coverage for prediction intervals constructed according to the quantiles of the normal distribution. Each plot corresponds to a separate distribution for setting-specific variation.

## 5 Discussion

In this work, we extend recent developments in causally-interpretable meta-analysis to account for between-study heterogeneity beyond covariate differences between trials and the target population. Our causal framework attempts to bridge the structure of traditional random-effects meta-analysis with causal inference. To do so, we introduce novel estimands, estimates, and inferential procedures that all explicitly reference the role that a trial’s setting can play in driving systematic differences between study-specific parameters.

The impact of between-study heterogeneity can severely limit the interpretability of treatment effect estimates transported from a collection of trials to the target population. Under such heterogeneity, estimates derived from data pooled across distinct trials may reflect a combination of the idiosyncrasies present in each trial setting. In many contexts, such heterogeneity persists despite standardizing the trial covariate distributions to that of a target population. For instance, variation in treatment version could cause differences in the potential outcomes we would expect to observe across studies, even after conditioning on all effect-modifiers, as well as covariates relevant to treatment selection or trial participation.

To address these issues, we begin by defining potential outcomes that explicitly reference setting-specific heterogeneity and, subsequently, construct estimators and inferential procedures that take this additional variability into account. By allowing potential outcomes to depend on both assigned treatment and the setting of that assignment, we can disaggregate the effects of a trial from the trial’s population.

Our work is a first step toward clarifying the dual influence of trial setting and participants in the context of causally-interpretable meta-analysis. With additional information about protocol-level differences between trials, our framework might be extended to reference specific trial characteristics of interest. Future work might consider transporting or up-weighting a specific source of heterogeneity (e.g. differing levels of adherence) to produce transported effects most relevant to the clinical setting of interest. Relatedly, it is also important to clarify the distinction between intention-to-treat and per-protocol effects when attempting to account for setting-specific heterogeneity. That is, investigators should distinguish between studying what would happen if a member of the target population had participated in a given trial and was compliant or was simply assigned treatment. The estimands introduced in this work should be interpreted as defining intention-to-treat transported effects, as our observed data contains information on treatment assignment alone. However, these methods may be extended to describe per-protocol effects when such data are available.

In part, our work follows from a simple acknowledgment that the particular context of an RCT has relevance for causal interpretability. In other words, estimates transported from RCTs do not necessarily have a generic interpretation uncoupled from the effects of trial setting. We view our framework as one step toward developing a causal structure that can accommodate between-study heterogeneity. In the future,

we aim to expand on this structure to incorporate trial-specific information relevant to a variety of clinical questions in populations of interest.

## References

- Berlin, Jesse A., and Robert M. Golub. 2014. “Meta-Analysis as Evidence: Building a Better Pyramid.” *JAMA* 312 (6): 603. <https://doi.org/10.1001/jama.2014.8167>.
- Dahabreh, Issa J., Lucia C. Petito, Sarah E. Robertson, Miguel A. Hernán, and Jon A. Steingrimsdóttir. 2020. “Toward Causally Interpretable Meta-Analysis: Transporting Inferences from Multiple Randomized Trials to a New Target Population.” *Epidemiology* 31 (3): 334–44. <https://doi.org/10.1097/EDE.0000000000001177>.
- Dahabreh, Issa J., Sarah E. Robertson, and Miguel A. Hernán. 2022. “Generalizing and Transporting Inferences about the Effects of Treatment Assignment Subject to Non-Adherence.” <https://arxiv.org/abs/2211.04876>.
- Dahabreh, Issa J., Sarah E. Robertson, Lucia C. Petito, Miguel A. Hernán, and Jon A. Steingrimsdóttir. 2022. “Efficient and Robust Methods for Causally Interpretable Meta-Analysis: Transporting Inferences from Multiple Randomized Trials to a Target Population.” *Biometrics*. <https://doi.org/https://doi.org/10.1111/biom.13716>.
- Dahabreh, Issa J., James M. Robins, Sebastien J.-P. A. Haneuse, and Miguel A. Hernán. 2019. “Generalizing Causal Inferences from Randomized Trials: Counterfactual and Graphical Identification.” arXiv. <http://arxiv.org/abs/1906.10792>.
- Degtiar, Irina, and Sherri Rose. 2021. “A Review of Generalizability and Transportability.” <https://doi.org/10.48550/ARXIV.2102.11904>.
- DerSimonian, Rebecca, and Nan Laird. 1986. “Meta-Analysis in Clinical Trials.” *Controlled Clinical Trials* 7 (3): 177–88.
- Dhruva, Sanket S. 2008. “Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence Used for Medicare National Coverage Decisions.” *Archives of Internal Medicine* 168 (2): 136. <https://doi.org/10.1001/archinternmed.2007.56>.
- Ebell, Mark H, Jay Siwek, Barry D Weiss, Steven H Woolf, Jeffrey Susman, Bernard Ewigman, and Marjorie Bowman. 2004. “Strength of Recommendation Taxonomy (SORT): A Patient-Centered Approach to Grading Evidence in the Medical Literature.” *The Journal of the American Board of Family Practice* 17 (1): 59–67.
- Galson, Steven, and Gregory Simon. 2016. “Real-World Evidence to Guide the Approval and Use of New Treatments.” *NAM Perspectives* 6 (10). <https://doi.org/10.31478/201610b>.

- Higgins, Julian P. T., Simon G. Thompson, and David J. Spiegelhalter. 2009. “A Re-Evaluation of Random-Effects Meta-Analysis.” *Journal of the Royal Statistical Society. Series A (Statistics in Society)* 172 (1): 137–59. <http://www.jstor.org/stable/30136745>.
- Kay, Stanley R., Abraham Fiszbein, and Lewis A. Opler. 1987. “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia.” *Schizophrenia Bulletin* 13 (2): 261–76. <https://doi.org/10.1093/schbul/13.2.261>.
- Lunny, Carole, Cynthia Ramasubbu, Lorri Puil, Tracy Liu, Savannah Gerrish, Douglas M. Salzwedel, Barbara Mintzes, and James M. Wright. 2021. “Over Half of Clinical Practice Guidelines Use Non-Systematic Methods to Inform Recommendations: A Methods Study.” Edited by Tim Mathes. *PLOS ONE* 16 (4): e0250356. <https://doi.org/10.1371/journal.pone.0250356>.
- Matsouaka, Roland A., Yi Liu, and Yunji Zhou. 2022. “Variance Estimation for the Average Treatment Effects on the Treated and on the Controls.” arXiv. <https://doi.org/10.48550/ARXIV.2209.10742>.
- Rao, Poduri S. R. S., Jack Kaplan, and William G. Cochran. 1981. “Estimators for the One-Way Random Effects Model with Unequal Error Variances.” *Journal of the American Statistical Association* 76 (373): 89–97. <http://www.jstor.org/stable/2287050>.
- Stadler, Eva, Khai Li Chai, Timothy E Schlub, Deborah Cromer, Mark N Polizzotto, Stephen J Kent, Nicole Skoetz, et al. 2022. “Determinants of Passive Antibody Effectiveness in SARS-CoV-2 Infection.” *medRxiv*. <https://doi.org/10.1101/2022.03.21.22272672>.
- Tsiatis, Anastasios A. 2006. “Semiparametric Theory and Missing Data.”
- U.S. Food and Drug Administration. 2021. “FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency.” Guidance for Industry, Investigators, and Institutional Review Boards FDA-2020-D-1106-0002.
- Vale, C. L., L. H. M. Rydzewska, M. M. Rovers, J. R. Emberson, F. Gueyffier, L. A. Stewart, and on behalf of the Cochrane IPD Meta-analysis Methods Group. 2015. “Uptake of Systematic Reviews and Meta-Analyses Based on Individual Participant Data in Clinical Practice Guidelines: Descriptive Study.” *BMJ* 350 (mar06 6): h1088–88. <https://doi.org/10.1136/bmj.h1088>.
- VanderWeele, Tyler J., and Miguel A. Hernán. 2013. “Causal Inference Under Multiple Versions of Treatment.” *Journal of Causal Inference* 1 (1): 1–20. <https://doi.org/doi:10.1515/jci-2012-0002>.

## Acknowledgements

The authors acknowledge the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing resources that contributed to the research results reported within this paper. URL: <http://www.msi.umn.edu>



## 6 Appendix

### 6.1 Full proof of identification formula result for $\mu_{a,0}(k_s^a)$

$$\begin{aligned}
E[Y(a, k_s^a)|R = 0] &= E[E[Y(a, k_s^a)|X, R = 0]|R = 0] && \text{Law of total expectation} \\
&= E[E[Y(a, k_s^a)|X, S = s]|R = 0] && \text{By Assumption 1} \\
&= E[E[Y(a, k_s^a)|X, S = s, A = a]|R = 0] && \text{By Assumption 2} \\
&= E[E[Y(a, k_s^a)|X, S = s, A = a, K^a(a) = k_s^a]|R = 0] && \text{By Assumption 5} \\
&= E[E[Y|X, S = s, A = a]|R = 0] && \text{By Assumption 3}
\end{aligned}$$

### 6.2 Full derivation of the approximation of $E[Y(a, K_0^a(a))|R = 0]$

$$\begin{aligned}
E[Y(a, K_0^a(a))|R = 0] &= \sum_{k^a \in \mathcal{K}^a} E\{E[Y(a, K_0^a(a))|R = 0, K_0^a(a) = k^a]|R = 0\} P(K_0^a(a) = k^a) \\
&\approx \sum_{k^a \in \mathcal{K}^a} E\{E[Y(a, K_0^a(a))|R = 0, K_0^a(a) = k^a]|R = 0\} \hat{P}(K_0^a(a) = k^a) \\
&= \sum_{k^a \in \mathcal{K}^a} E\{E[Y(a, K_0^a(a))|R = 0, K_0^a(a) = k^a]|R = 0\} \left\{ \frac{1}{m} \sum_{s=1}^m \mathbb{1}(k^a = k_s^a) \right\} \\
&= \sum_{k^a \in \mathcal{K}^a} \frac{1}{m} \sum_{s=1}^m \mathbb{1}(k^a = k_s^a) E\{E[Y(a, K_s^a(a))|R = 0, K_s^a(a) = k^a]|R = 0\} \\
&= \frac{1}{m} \sum_{s=1}^m \sum_{k^a \in \mathcal{K}^a} \mathbb{1}(k^a = k_s^a) E\{E[Y(a, K_s^a(a))|R = 0, K_s^a(a) = k^a]|R = 0\} \\
&= \frac{1}{m} \sum_{s=1}^m E\{E[Y(a, K_s^a(a))|R = 0, K_s^a(a) = k_s^a]|R = 0\} \\
&= \frac{1}{m} \sum_{s=1}^m E[Y(a, k_s^a)|R = 0] \\
&= \frac{1}{m} \sum_{s=1}^m E[E[Y|X, S = s, A = a]|R = 0] && \text{By (7)}
\end{aligned}$$

### 6.3 Full derivation of our estimate of between-study variance in the presence of correlated estimates

Applying the notation defined in the main manuscript, write the overall sum of squares of our estimators as

$$Q = \sum_{s=1}^m (\hat{\mu}_s - \hat{\mu})^2 = \sum_{s=1}^m \left( \hat{\mu}_s - \sum_{l=1}^m w_l \hat{\mu}_l \right)^2$$

and

$$Q_s = (\hat{\mu}_s - \hat{\mu})^2 = \left( \hat{\mu}_s - \sum_{l=1}^m w_l \hat{\mu}_l \right)^2.$$

Thus,  $Q = \sum_{s=1}^m Q_s$ . As in Rao, Kaplan, and Cochran (1981), we derive an expression for the expectation of  $Q$  and an estimator for  $\gamma^2$ . To that end, let

$$\mathbf{a}_s = \begin{pmatrix} -w_1 \\ \vdots \\ 1 - w_s \\ \vdots \\ -w_m \end{pmatrix}$$

and

$$\Sigma = \begin{pmatrix} \sigma_1^2 + \gamma^2 & \sigma_{12} & \cdots & \sigma_{1m} \\ \sigma_{12} & \sigma_2^2 + \gamma^2 & \cdots & \sigma_{2m} \\ \vdots & \vdots & \ddots & \vdots \\ \sigma_{1m} & \sigma_{2m} & \cdots & \sigma_m^2 + \gamma^2 \end{pmatrix}$$

be the variance-covariance matrix for  $\hat{\mu}$  with  $\sigma_i^2 + \gamma^2$  as the  $i$ th diagonal entry and  $\sigma_{ij}$  as the  $(i, j)$  off diagonal entry (i.e.  $\sigma_{ij}$  is  $\text{Cov}(\hat{\mu}_i, \hat{\mu}_j)$ ). Then,

$$\begin{aligned} \mathbf{a}_s \mathbf{a}_s^T \Sigma &= \begin{pmatrix} -w_1 \\ \vdots \\ 1 - w_s \\ \vdots \\ -w_m \end{pmatrix} \begin{pmatrix} -w_1 & \cdots & 1 - w_s & \cdots & -w_m \end{pmatrix} \begin{pmatrix} \sigma_1^2 + \gamma^2 & \sigma_{12} & \cdots & \sigma_{1m} \\ \sigma_{12} & \sigma_2^2 + \gamma^2 & \cdots & \sigma_{2m} \\ \vdots & \vdots & \ddots & \vdots \\ \sigma_{1m} & \sigma_{2m} & \cdots & \sigma_m^2 + \gamma^2 \end{pmatrix} \\ &= \begin{pmatrix} w_1^2 & \cdots & -w_1(1 - w_s) & \cdots & w_1 w_m \\ \vdots & \vdots & \vdots & \vdots & \vdots \\ -w_1(1 - w_s) & \cdots & (1 - w_s)^2 & \cdots & -w_m(1 - w_s) \\ \vdots & \vdots & \vdots & \vdots & \vdots \\ w_1 w_m & \cdots & -w_m(1 - w_s) & \cdots & w_m^2 \end{pmatrix} \begin{pmatrix} \sigma_1^2 + \gamma^2 & \sigma_{12} & \cdots & \sigma_{1m} \\ \sigma_{12} & \sigma_2^2 + \gamma^2 & \cdots & \sigma_{2m} \\ \vdots & \vdots & \ddots & \vdots \\ \sigma_{1m} & \sigma_{2m} & \cdots & \sigma_m^2 + \gamma^2 \end{pmatrix}. \end{aligned}$$

That is, after computing  $\mathbf{a}_s \mathbf{a}_s^T$ , we obtain a matrix where the  $i$ th diagonal entry is  $w_i^2$  except for the  $s$ th such entry which is  $(1 - w_s)^2$ . In each row  $i$ ,  $i \neq s$ , entries  $(i, j)$ ,  $j \neq s$  and  $j \neq i$  are given by  $w_i w_j$  while entry  $(i, s)$  is  $-w_i(1 - w_s)$ . In the  $s$ th row, each entry  $(s, j)$ ,  $j \neq s$  is  $-w_j(1 - w_s)$ . To compute  $E[Q_s]$ , we need to

compute  $\text{tr}(\mathbf{a}_s \mathbf{a}_s^T \Sigma)$ . Looking at the matrices in the second equality above, taking the dot product of the first row in the matrix of weights with the first column of  $\Sigma$  we can see that the  $i$ th such diagonal entry ( $i \neq s$ )

$$w_i^2(\sigma_i^2 + \gamma^2) - w_i(1 - w_s)(\sigma_{is}) + \sum_{j \neq i, j \neq s} w_i w_j \sigma_{ij}.$$

The  $s$ th diagonal entry is then

$$(1 - w_s)^2(\sigma_s^2 + \gamma^2) + \sum_{i \neq s} (-w_i)(1 - w_s)\sigma_{is}.$$

Summing all the diagonal entries,

$$\begin{aligned} \text{tr}(\mathbf{a}_s \mathbf{a}_s^T \Sigma) &= (1 - w_s)^2(\sigma_s^2 + \gamma^2) + \sum_{i \neq s} (-w_i)(1 - w_s)\sigma_{is} + \sum_{i \neq s} \left[ w_i^2(\sigma_i^2 + \gamma^2) - w_i(1 - w_s)(\sigma_{is}) + \sum_{j \neq i, j \neq s} w_i w_j \sigma_{ij} \right] \\ &= (1 - 2w_s)(\sigma_s^2 + \gamma^2) + \sum_{i=1}^m w_i^2(\sigma_i^2 + \gamma^2) - 2 \sum_{i \neq s} w_i(1 - w_s)\sigma_{is} + \sum_{i \neq s} \left[ \sum_{j \neq i, j \neq s} w_i w_j \sigma_{ij} \right]. \end{aligned}$$

Now the question is: how can we compute  $\gamma^2$  using the moment equations? To begin, let

$$C_s = -2 \sum_{i \neq s} w_i(1 - w_s)\sigma_{is} + \sum_{i \neq s} \left[ \sum_{j \neq i, j \neq s} w_i w_j \sigma_{ij} \right]$$

denote all the components of  $\text{tr}(\mathbf{a}_s \mathbf{a}_s^T \Sigma)$  that are constant as a function of  $\gamma^2$ . Then, recognizing that

$\boldsymbol{\mu}^T \mathbf{a}_i \mathbf{a}_i^T \boldsymbol{\mu} = 0$ , we have

$$E[Q_s] = (1 - 2w_s)(\sigma_s^2 + \gamma^2) + \sum_{i=1}^m w_i^2(\sigma_i^2 + \gamma^2) + C_s$$

and, moreover,

$$\begin{aligned} E[Q] &= \sum_{s=1}^m E[Q_s] \\ &= \sum_{s=1}^m \left[ (1 - 2w_s)(\sigma_s^2 + \gamma^2) + \sum_{i=1}^m w_i^2(\sigma_i^2 + \gamma^2) + C_s \right] \\ &= m \sum_{s=1}^m w_s^2(\sigma_s^2 + \gamma^2) + \sum_{s=1}^m [(1 - 2w_s)(\sigma_s^2 + \gamma^2) + C_s]. \end{aligned}$$

We apply this expression for  $E[Q]$  to derive the estimate for between-study heterogeneity given in the main part of the paper.

## 6.4 Identification for IPW estimator

This identification result proceeds similarly to the analogous IPW identification result in Dahabreh et al. (2022). The important distinction is that the weights are distinct for each trial, rather than applying to all members of the trial population. The result below follows from application of iterated expectation and our positivity assumption (Assumption 4).

$$\begin{aligned}
\psi_{s,0}(a) &= E[E[Y|X, S = s, A = a]|R = 0] \\
&= E \left[ E \left[ \frac{I(S = s, A = a)Y}{P(S = s|X)P(A = a|X, S = s)} \middle| X \right] \middle| R = 0 \right] \\
&= \frac{1}{P(R = 0)} E \left[ I(R = 0) E \left[ \frac{I(S = s, A = a)Y}{P(S = s|X)P(A = a|X, S = s)} \middle| X \right] \right] \\
&= \frac{1}{P(R = 0)} E \left[ E \left[ \frac{I(S = s, A = a)YP(R = 0|X)}{P(S = s|X)P(A = a|X, S = s)} \middle| X \right] \right] \\
&= \frac{1}{P(R = 0)} E \left[ E \frac{I(S = s, A = a)YP(R = 0|X)}{P(S = s|X)P(A = a|X, S = s)} \right]
\end{aligned}$$

## 6.5 Full Simulation Results: Quantile-Based Prediction Intervals

N Studies	Distribution of Delta	Method of Moments		Simple Bootstrap		Wild Bootstrap	
		Coverage	Length	Coverage	Length	Coverage	Length
5	Exponential(1)-1	92.8%	5.55	88.9%	3.24	88.8%	3.29
5	Normal(0, 1)	95%	5.91	83.5%	3.45	83.8%	3.50
5	Pareto(1, 3)	89.6%	3.84	90.9%	2.50	91%	2.54
5	Uniform(-2, 2)	96.4%	7.03	86.6%	3.91	87.5%	3.95
10	Exponential(1)-1	93.5%	4.38	93.6%	3.68	94.4%	3.77
10	Normal(0, 1)	94.3%	4.51	89.4%	3.79	91%	3.87
10	Pareto(1, 3)	89.7%	2.80	92.7%	2.65	93.5%	2.76
10	Uniform(-2, 2)	97.9%	5.26	93.8%	4.03	94.2%	4.12
15	Exponential(1)-1	93.4%	4.08	95%	3.83	95.5%	3.95
15	Normal(0, 1)	94.2%	4.30	92%	4.00	92.7%	4.08
15	Pareto(1, 3)	91.7%	2.74	95%	2.90	95.5%	3.02
15	Uniform(-2, 2)	98.3%	4.98	94.8%	4.07	95.7%	4.18
30	Exponential(1)-1	95.5%	3.96	98.1%	4.20	97.7%	4.26
30	Normal(0, 1)	95.2%	4.07	94.2%	4.16	94.5%	4.19
30	Pareto(1, 3)	95.4%	2.81	97.5%	3.46	97.6%	3.54
30	Uniform(-2, 2)	98.6%	4.71	96.2%	4.03	98.2%	4.18
50	Exponential(1)-1	93.8%	3.96	96.9%	3.96	96.8%	4.13
50	Normal(0, 1)	94.5%	4.00	94%	4.06	94.6%	4.18
50	Pareto(1, 3)	94.5%	2.98	96%	2.97	96.7%	3.21
50	Uniform(-2, 2)	99.3%	4.64	97.6%	4.03	98.8%	4.21

## 6.6 Full Simulation Results: Normal-Based Prediction Intervals

		Method of Moments		Simple Bootstrap		Wild Bootstrap	
N Studies	Distribution of Delta	Coverage	Length	Coverage	Length	Coverage	Length
5	Exponential(1)-1	92.8%	5.55	91%	4.04	91.1%	4.06
5	Normal(0, 1)	95%	5.91	88.9%	4.25	89%	4.26
5	Pareto(1, 3)	89.6%	3.84	91.3%	3.03	91.5%	3.03
5	Uniform(-2, 2)	96.4%	7.03	91.9%	4.99	91.8%	5.00
10	Exponential(1)-1	93.5%	4.38	93.3%	4.09	93.6%	4.13
10	Normal(0, 1)	94.3%	4.51	92.6%	4.19	92.9%	4.23
10	Pareto(1, 3)	89.7%	2.80	91.5%	2.81	92.1%	2.88
10	Uniform(-2, 2)	97.9%	5.26	96.5%	4.83	96.5%	4.86
15	Exponential(1)-1	93.4%	4.08	93.5%	3.99	93.7%	4.05
15	Normal(0, 1)	94.2%	4.30	93.4%	4.17	93.8%	4.23
15	Pareto(1, 3)	91.7%	2.74	93.8%	2.83	94%	2.92
15	Uniform(-2, 2)	98.3%	4.98	97.7%	4.79	97.9%	4.85
30	Exponential(1)-1	95.5%	3.96	95.7%	4.00	96.1%	4.08
30	Normal(0, 1)	95.2%	4.07	95.4%	4.09	95.9%	4.17
30	Pareto(1, 3)	95.4%	2.81	95.8%	2.95	96.4%	3.08
30	Uniform(-2, 2)	98.6%	4.71	98.7%	4.69	98.9%	4.77
50	Exponential(1)-1	93.8%	3.96	94.4%	4.03	94.8%	4.14
50	Normal(0, 1)	94.5%	4.00	94.7%	4.07	95.6%	4.17
50	Pareto(1, 3)	94.5%	2.98	95.3%	3.12	95.6%	3.29
50	Uniform(-2, 2)	99.3%	4.64	99.5%	4.68	99.6%	4.78